向RON激酶 (MST1R) 的异型驱动抗瘤疗效
Joseph Kim1,2,3, Dong-In Koh1,2, Minki Lee1,2
1Wellmarkerbio Co., Ltd., Seoul, Republic of Korea.
Cell death and differentiation
|November 5, 2023
概括
一种新的抑制剂,WM-S1-030,向激活的nantais起源受体 (RON) 拼接变体,显示出克服抗EGFR治疗耐药性和增强固体瘤免疫治疗的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 源纳泰斯受体 (RON,MST1R) 是一种受体氨酸激酶 (RTK),与各种癌症有关.
- 在瘤发生和治疗耐药性方面,RON拼接变异的作用仍然在很大程度上是未知的.
研究的目的:
- 研究RON拼接变种对结直肠癌抗EGFR治疗耐药性的影响.
- 阐明RON变体 (Δ155, Δ160, Δ165) 的致癌机制.
- 评估一种新型RON抑制剂WM-S1-030.的治疗潜力.
主要方法:
- 对大肠直肠癌患者组织进行激活RON的分析.
- 在癌细胞系中对RON拼接变体 (Δ155, Δ160, Δ165) 的表征.
- 在实验室和体内WM-S1-030在固体瘤模型中的疗效研究.
- 研究RON介导的信号通路 (EGFR,Src,β-catenin) 和免疫调节作用.
主要成果:
- 激活的RON与结直肠癌中抗EGFR治疗的耐药性相关.
- RON变体 Δ155, Δ160 和 Δ165 起到瘤驱动的作用.
- WM-S1-030有效地抑制RON变体和野生型RON,导致瘤回归.
- 在抗PD-1耐药模型中,WM-S1-030显示出抗瘤免疫力,可能是通过巨细胞极化调节.
结论:
- WM-S1-030对表达RON变异的固体瘤表现出强大的抗瘤活性.
- 该抑制剂显示出克服治疗耐药性和增强免疫治疗的潜力.
- WM-S1-030代表了针对具有特定RON变异表达的癌症的有前途的新治疗策略.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
